# Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

> **NCT05801107** · PHASE2 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** WX-0593

## Key facts

- **NCT ID:** NCT05801107
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-25
- **Primary completion:** 2023-07-15
- **Final completion:** 2023-12-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05801107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05801107, "Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05801107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*